- Home
- MCY vs GH Comparison
MCY vs GH Comparison
Compare MCY & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCY
- GH
- Stock Information
- Founded
- MCY 1961
- GH 2011
- Country
- MCY United States
- GH United States
- Employees
- MCY N/A
- GH N/A
- Industry
- MCY Property-Casualty Insurers
- GH Medical Specialities
- Sector
- MCY Finance
- GH Health Care
- Exchange
- MCY Nasdaq
- GH Nasdaq
- Market Cap
- MCY 3.7B
- GH 4.3B
- IPO Year
- MCY N/A
- GH 2018
- Fundamental
- Price
- MCY $67.47
- GH $34.02
- Analyst Decision
- MCY
- GH Strong Buy
- Analyst Count
- MCY 0
- GH 15
- Target Price
- MCY N/A
- GH $39.93
- AVG Volume (30 Days)
- MCY 242.8K
- GH 1.6M
- Earning Date
- MCY 02-11-2025
- GH 11-06-2024
- Dividend Yield
- MCY 1.89%
- GH N/A
- EPS Growth
- MCY N/A
- GH N/A
- EPS
- MCY 10.08
- GH N/A
- Revenue
- MCY $5,470,287,000.00
- GH $692,256,000.00
- Revenue This Year
- MCY N/A
- GH $32.23
- Revenue Next Year
- MCY $6.09
- GH $16.90
- P/E Ratio
- MCY $6.69
- GH N/A
- Revenue Growth
- MCY 24.14
- GH 29.20
- 52 Week Low
- MCY $36.96
- GH $15.81
- 52 Week High
- MCY $80.72
- GH $38.53
- Technical
- Relative Strength Index (RSI)
- MCY 33.25
- GH 58.28
- Support Level
- MCY $71.50
- GH $34.20
- Resistance Level
- MCY $74.75
- GH $36.24
- Average True Range (ATR)
- MCY 2.27
- GH 1.40
- MACD
- MCY -1.16
- GH -0.54
- Stochastic Oscillator
- MCY 1.16
- GH 12.70
About MCY Mercury General Corporation
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.